Inclusion Criteria:

Pts have baseline evaluations ≤14days prior to 1st dose of study drug unless otherwise specified

• Pts w confirmed MG who are recurrence/relapse
• Pts may not have stereotactic tumor biopsy <2wk/surgical resection/open biopsy <4wks before starting study drug
• For stratum of non-EIAED pts, each pt must be off all EIAEDs for >2wks prior to starting study drug; similarly for stratum of EIAED pts, each pt must be on EIAED for >2 wks prior to starting study drug
• Pts should be on non-increasing dose of steroids for >7 days prior to obtaining baseline Gd-MRI of brain
• Pts should be on non-increasing dose of steroids for >7 days prior to starting study drug
• Multifocal disease is eligible
• Age ≥18yrs
• KPS >70
• Absolute Neutrophil Count >1.0 x 10 9/L
• Hgb >9 g/dL
• Platelets >100 x 10 9/L
• Serum creatinine >1.5 x ULN or measured 24-hr CrCl >50mL/min/1.73m2
• Life expectancy ≥12wks
• Written informed consent obtained prior to screening procedures
• Negative Beta-HCG pregnancy test for women of child-bearing potential

Exclusion Criteria:

• Serum direct bilirubin >1.5 x ULN of reference range
• Serum creatinine >1.5 x ULRR & CrCl <30 mL/min
• Potassium, <4.0 mmol/L despite supplementation; serum calcium, /Mg out of normal range despite supplementation, Sodium <130 mmol/L
• ALT or AST > 2.5 x ULRR or > 5 x ULRR if judged by investigator to be related to liver metastases

• PT or PTT >1.5 x ULN of reference range

  -Evidence of severe/uncontrolled systemic disease or any concurrent condition which in Investigator's opinion makes it undesirable for pt to participate in trial/which would jeopardize compliance w protocol

• Clinically significant cardiovascular event such as myocardial infarction, superior vena cava syndrome, New York Heart Association classification of heart disease >2 within 3 months before entry; or presence of cardiac disease that, in opinion of Investigator, increases risk of ventricular arrhythmia
• History of arrhythmia which is symptomatic/requires treatment/asymptomatic sustained ventricular tachycardia. Atrial fibrillation, controlled on medication is not excluded
• Previous history of QTc prolongation as result from other medication that required discontinuation of that medication
• Congenital long QT syndrome, or 1st degree relative w unexplained sudden death <40yrs
• Presence of left bundle branch block
• Any concomitant medication that may cause QTc prolongation, induce Torsades de Pointes/induce CYP3A4 function except for EIAEDs
• Hypertension not controlled by medical therapy
• Currently active diarrhea that may affect ability of pt to absorb study regimen/tolerate diarrhea
• Women who are currently pregnant/breast feeding
• Previous/current malignancies of other histologies <5yrs, w exception of cervical carcinoma in situ & adequately treated basal cell/ squamous cell carcinoma of skin
• Receipt of any investigational agents <30 days prior to commencing study treatment unless pt has recovered from all anticipated toxicities of investigational agent
• Last dose of prior chemo discontinued <4wks before start of study therapy unless pt has recovered from all anticipated toxicities of chemo
• Last XRT <4wks before start of study therapy, unless pt has recovered from all anticipated toxicities of XRT
• Any unresolved toxicity >CTC gr1 from previous anti-cancer therapy
• Previous enrollment/randomization of treatment in present study
• Major surgery <4wks/incompletely healed surgical incision before starting study therapy
• Pts taking warfarin sodium